During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1. The candidate is a live replicating virus vaccine using a vaccinia virus vector.
During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1. The candidate is a live attenuated virus vaccine using a vaccinia virus vector.